Dermatomycoses: Comprehensive Global Clinical Trials Analytics H2 2018

“GervanoRA’s Clinical trials report “Dermatomycoses: Comprehensive Global Clinical Trials Analytics H2 2018” provides an in-depth analysis of the overall clinical trials for Dermatomycoses. The report caters information related to the global clinical trials with respect to their Phase, Trial Status, Intervention, Trial type and Endpoint status. Our report exclusively focuses on providing insights and competitive opportunities based on Biomarker or target receptor, Drug Class and Mechanism of Action to aid in understanding the upcoming newer research trends in the field of Dermatomycoses drug discovery. The report offers coverage of Dermatomycoses clinical trials by region and average enrollment by country. Country based analytics are provided according to the Top 5 Clinical trial sites globally and the emerging countries supporting with a platform to conduct clinical trials effectively. Analytics are also provided for the subjects enrolled over a period of time, Dermatomycoses clinical trials by sponsor type and the top companies involved in the R&D of Dermatomycoses drug development. In addition, the report gives a brief overview on the major drugs undergoing trials and the recent advancements observed in the Dermatomycoses clinical trials.

TABLE OF CONTENTS
1. INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. RESEARCH METHODOLOGY
1.3. UPCOMING AND OTHER AVAILABLE REPORTS
1.4. ABOUT US: GERVANORA DATA SERVICES
2. GERVANORA CLINICAL TRIALS REPORT COVERAGE
3. EXECUTIVE SUMMARY
3.1 MAJOR FINDINGS
3.2 TRIALS EXPECTED TO COMPLETE IN 5 YEARS
4. DERMATOMYCOSES CLINICAL TRIALS ANALYTICS BASED ON BIOMARKERS OR TARGET RECEPTOR
4.1 PHASE 3 CLINICAL TRIALS ANALYTICS BASED ON BIOMARKERS OR TARGET RECEPTOR
4.2 PHASE 2 CLINICAL TRIALS ANALYTICS BASED ON BIOMARKERS OR TARGET RECEPTOR
4.3 PHASE 1 CLINICAL TRIALS ANALYTICS BASED ON BIOMARKERS OR TARGET RECEPTOR
5. DERMATOMYCOSES CLINICAL TRIALS ANALYTICS BASED ON DRUG CLASS
5.1 PHASE 3 CLINICAL TRIALS ANALYTICS BASED ON DRUG CLASS
5.2 PHASE 2 CLINICAL TRIALS ANALYTICS BASED ON DRUG CLASS
5.3 PHASE 1 CLINICAL TRIALS ANALYTICS BASED ON DRUG CLASS
6. DERMATOMYCOSES CLINICAL TRIALS ANALYTICS BASED ON MECHANISM OF ACTION
6.1 PHASE 3 CLINICAL TRIALS ANALYTICS BASED ON MECHANISM OF ACTION
6.2 PHASE 2 CLINICAL TRIALS ANALYTICS BASED ON MECHANISM OF ACTION
6.3 PHASE 1 CLINICAL TRIALS ANALYTICS BASED ON MECHANISM OF ACTION
7. DERMATOMYCOSES CLINICAL TRIALS BY PHASE
7.1 ONGOING CLINICAL TRIALS BY PHASE
7.2 COMPLETED CLINICAL TRIALS BY PHASE
7.3 UPCOMING CLINICAL TRIALS BY PHASE (NOT YET RECRUITING)
8. DERMATOMYCOSES CLINICAL TRIALS BY REGION
9. DERMATOMYCOSES CLINICAL TRIALS BY TRIAL STATUS (INCLUDING EXPANDED ACCESS)
10. DERMATOMYCOSES CLINICAL TRIALS BY INTERVENTION
11. DERMATOMYCOSES CLINICAL TRIALS BY TYPE
12. DERMATOMYCOSES CLINICAL TRIALS BY ENDPOINT STATUS
13. DERMATOMYCOSES CLINICAL TRIALS AND AVERAGE ENROLLMENT BY COUNTRY
13.1 ANALYTICS BY TOP 5 CLINICAL TRIAL SITES
13.1.1 CLINICAL TRIAL ANALYTICS BY PHASE AND TRIAL STATUS IN THE US
13.1.2 CLINICAL TRIAL ANALYTICS BY PHASE AND TRIAL STATUS IN GERMANY
13.1.3 CLINICAL TRIAL ANALYTICS BY PHASE AND TRIAL STATUS IN JAPAN
13.1.4 CLINICAL TRIAL ANALYTICS BY PHASE AND TRIAL STATUS IN FRANCE
13.1.5 CLINICAL TRIAL ANALYTICS BY PHASE AND TRIAL STATUS IN SPAIN
13.2 ANALYTICS BY EMERGING CLINICAL TRIAL SITES
13.2.1 CLINICAL TRIAL ANALYTICS BY PHASE AND TRIAL STATUS IN CHINA
13.2.2 CLINICAL TRIAL ANALYTICS BY PHASE AND TRIAL STATUS IN INDIA
13.2.3 CLINICAL TRIAL ANALYTICS BY PHASE AND TRIAL STATUS IN RUSSIA
13.2.4 CLINICAL TRIAL ANALYTICS BY PHASE AND TRIAL STATUS IN AUSTRALIA
13.2.5 CLINICAL TRIAL ANALYTICS BY PHASE AND TRIAL STATUS IN BRAZIL
13.2.6 CLINICAL TRIAL ANALYTICS BY PHASE AND TRIAL STATUS IN CHILE
13.2.7 CLINICAL TRIAL ANALYTICS BY PHASE AND TRIAL STATUS IN AFRICA
13.2.8 CLINICAL TRIAL ANALYTICS BY PHASE AND TRIAL STATUS IN MIDDLE EAST
14. SUBJECTS RECRUITED OVER A PERIOD OF TIME
15. DERMATOMYCOSES CLINICAL TRIALS BY SPONSOR TYPE
15.1. TOP COMPANIES PARTICIPATING IN DERMATOMYCOSES CLINICAL TRIALS
16. MAJOR DRUGS UNDERGOING TRIALS
17. RECENT ADVANCEMENTS IN DERMATOMYCOSES CLINICAL TRIALS
18. ABBREVIATIONS
LIST OF TABLES:
TABLE 01: DERMATOMYCOSES CLINICAL TRIALS TO BE COMPLETED IN 5 YEARS
TABLE 02: BIOMARKERS OR TARGET RECEPTOR BASED CLINICAL TRIALS ANALYTICS
TABLE 03: BIOMARKERS OR TARGET RECEPTOR BASED CLINICAL TRIALS ANALYTICS, PHASE 3 HSD
TABLE 04: BIOMARKERS OR TARGET RECEPTOR BASED CLINICAL TRIALS ANALYTICS, PHASE 2 HSD
TABLE 05: BIOMARKERS OR TARGET RECEPTOR BASED CLINICAL TRIALS ANALYTICS, PHASE 1 HSD
TABLE 06: DRUG CLASS BASED DERMATOMYCOSES CLINICAL TRIALS ANALYTICS
TABLE 07: DRUG CLASS BASED DERMATOMYCOSES CLINICAL TRIALS ANALYTICS, PHASE 1
TABLE 08: DRUG CLASS BASED DERMATOMYCOSES CLINICAL TRIALS ANALYTICS, PHASE 2
TABLE 09: DRUG CLASS BASED DERMATOMYCOSES CLINICAL TRIALS ANALYTICS, PHASE 3
TABLE 10: MECHANISM OF ACTION BASED DERMATOMYCOSES CLINICAL TRIALS ANALYTICS
TABLE 11: DERMATOMYCOSES CLINICAL TRIALS ANALYTICS BASED ON HSD
TABLE 12: ONGOING CLINICAL TRIALS ANALYTICS BY HSD
TABLE 13: COMPLETED CLINICAL TRIALS ANALYTICS BY HSD
TABLE 14: UPCOMING CLINICAL TRIALS ANALYTICS BY HSD
TABLE 15: DERMATOMYCOSES CLINICAL TRIALS BY REGION
TABLE 16: DERMATOMYCOSES CLINICAL TRIALS BY TRIAL STATUS
TABLE 17: DERMATOMYCOSES CLINICAL TRIALS BY TYPE
TABLE 18: DERMATOMYCOSES CLINICAL TRIALS ANALYTICS, TOP 5 CLINICAL TRIAL SITES
TABLE 19: DERMATOMYCOSES CLINICAL TRIALS ANALYTICS IN THE US, PHASE AND TRIAL STATUS
TABLE 20: DERMATOMYCOSES CLINICAL TRIALS ANALYTICS IN GERMANY, PHASE AND TRIAL STATUS
TABLE 21: DERMATOMYCOSES CLINICAL TRIALS ANALYTICS IN JAPAN, PHASE AND TRIAL STATUS
TABLE 22: DERMATOMYCOSES CLINICAL TRIALS ANALYTICS IN FRANCE, PHASE AND TRIAL STATUS
TABLE 23: DERMATOMYCOSES CLINICAL TRIALS ANALYTICS IN SPAIN, PHASE AND TRIAL STATUS
TABLE 24: DERMATOMYCOSES CLINICAL TRIALS ANALYTICS, EMERGING CLINICAL TRIAL SITES
TABLE 25: DERMATOMYCOSES CLINICAL TRIALS ANALYTICS IN CHINA, PHASE AND TRIAL STATUS
TABLE 26: DERMATOMYCOSES CLINICAL TRIALS ANALYTICS IN INDIA, PHASE AND TRIAL STATUS
TABLE 27: DERMATOMYCOSES CLINICAL TRIALS ANALYTICS IN RUSSIA, PHASE AND TRIAL STATUS
TABLE 28: DERMATOMYCOSES CLINICAL TRIALS ANALYTICS IN AUSTRALIA, PHASE AND TRIAL STATUS
TABLE 29: DERMATOMYCOSES CLINICAL TRIALS ANALYTICS IN BRAZIL, PHASE AND TRIAL STATUS
TABLE 30: DERMATOMYCOSES CLINICAL TRIALS ANALYTICS IN CHILE, PHASE AND TRIAL STATUS
TABLE 31: DERMATOMYCOSES CLINICAL TRIALS ANALYTICS IN AFRICA, PHASE AND TRIAL STATUS
TABLE 32: DERMATOMYCOSES CLINICAL TRIALS ANALYTICS IN MIDDLE EAST, PHASE AND TRIAL STATUS
TABLE 33: DERMATOMYCOSES CLINICAL TRIALS BY SPONSOR TYPE
TABLE 34: DERMATOMYCOSES CLINICAL TRIALS, TOP COMPANIES
TABLE 35: ANALYTICS OF THE MAJOR DRUGS BY HIGHEST STAGE OF DEVELOPMENT
LIST OF FIGURES:
FIGURE 01: DERMATOMYCOSES CLINICAL TRIALS, BIOMARKERS OR TARGET RECEPTOR BASED SCENARIO
FIGURE 02: BIOMARKERS OR TARGET RECEPTOR SCENARIO, PHASE 3 CLINICAL TRIALS ANALYTICS
FIGURE 03: BIOMARKERS OR TARGET RECEPTOR SCENARIO, PHASE 2 CLINICAL TRIALS ANALYTICS
FIGURE 04: BIOMARKERS OR TARGET RECEPTOR SCENARIO, PHASE 1 CLINICAL TRIALS ANALYTICS
FIGURE 05: DERMATOMYCOSES CLINICAL TRIALS ANALYTICS BY DRUG CLASS
FIGURE 06: DERMATOMYCOSES CLINICAL TRIALS ANALYTICS, PHASE 3 HSD
FIGURE 07: DERMATOMYCOSES CLINICAL TRIALS ANALYTICS, PHASE 2 HSD
FIGURE 08: DERMATOMYCOSES CLINICAL TRIALS ANALYTICS, PHASE 1 HSD
FIGURE 09: DERMATOMYCOSES CLINICAL TRIALS ANALYTICS BY MECHANISM OF ACTION
FIGURE 10: CLINICAL TRIAL ANALYTICS, HSD SPLIT-UP
FIGURE 11: ONGOING CLINICAL TRIALS BY PHASE
FIGURE 12: COMPLETED CLINICAL TRIALS BY PHASE
FIGURE 13: UPCOMING CLINICAL TRIALS BY PHASE
FIGURE 14: DERMATOMYCOSES CLINICAL TRIALS BY REGION
FIGURE 15: DERMATOMYCOSES CLINICAL TRIALS BY TRIAL STATUS
FIGURE 16: DERMATOMYCOSES CLINICAL TRIALS BY TYPE
FIGURE 17: DERMATOMYCOSES CLINICAL TRIALS BY ENDPOINT STATUS
FIGURE 18: DERMATOMYCOSES CLINICAL TRIALS AND AVERAGE ENROLLMENT BY COUNTRY
FIGURE 19: CLINICAL TRIAL ANALYTICS BY TOP 5 CLINICAL TRIAL SITES
FIGURE 20: CLINICAL TRIAL ANALYTICS BY EMERGING CLINICAL TRIAL SITES
FIGURE 21: DERMATOMYCOSES CLINICAL TRIAL ANALYTICS, SPLIT BY SPONSOR TYPE